Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma

Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma

Natural killer/T-cell lymphoma (NKTCL) is an Epstein–Barr virus-associated non-Hodgkin lymphoma linked to an aggressive clinical course and poor prognosis. Despite an improvement in survival outcomes with the incorporation of novel agents including immune checkpoint inhibitors in the treatment of NK...

Full description

Bibliographic Details
Main Authors:	Jason Yongsheng Chan, Jing Quan Lim, Choon Kiat Ong
Format:	Article
Language:	English
Published:	MDPI AG 2021-08-01
Series:	Life
Subjects:	precision oncology PD-L1 immunotherapy prognosis EBV
Online Access:	https://www.mdpi.com/2075-1729/11/8/838

Similar Items

Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma
by: Daniel Ren Yi Yap, et al.
Published: (2023-01-01)

Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL)
by: Nagavalli Somasundaram, et al.
Published: (2019-03-01)

Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma
by: Esther Wei Yin Chang, et al.
Published: (2024-06-01)

Prognostic implications of circulating Epstein–Barr virus DNA for extranodal natural killer/T-cell lymphoma, nasal type: a meta-analysis
by: Chen RW, et al.
Published: (2018-07-01)

Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations
by: Jason Yongsheng Chan, et al.
Published: (2023-07-01)

Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma
by: Liqin Xu, et al.
Published: (2022-08-01)

Programmed death‐ligand 1 expression in Epstein‐Barr virus positive nasopharyngeal cancer
by: Abdulhameed Alfagih, et al.
Published: (2023-06-01)

Next‐generation Gene Silencers for Cancer Immunotherapy
by: Ng, Aik Seng
Published: (2017)

Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program
by: Massimo Granai, et al.
Published: (2020-05-01)

The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy
by: Jiajia Du, et al.
Published: (2024-04-01)

The biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma, NOS
by: Ji-Wei Li, et al.
Published: (2024-01-01)

PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis
by: Áurea Lima, et al.
Published: (2022-03-01)

Cutaneous Adverse Reactions and Survival Outcomes of Advanced Melanoma Treated with Immune Checkpoint Inhibitors in an Academic Medical Centre in Singapore
by: Agnes Yeok-Loo Lim, et al.
Published: (2024-07-01)

Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy
by: Shaoyan Lin, et al.
Published: (2024-07-01)

HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma
by: Guoming Chen, et al.
Published: (2023-02-01)

Statistical Process Control Charts for Monitoring Next-Generation Sequencing and Bioinformatics Turnaround in Precision Medicine Initiatives
by: Sneha Rajiv Jain, et al.
Published: (2021-09-01)

How Epstein Barr Virus Causes Lymphomas
by: Ya-Fang Chiu, et al.
Published: (2024-11-01)

Clinical significance and different strategies for re-elevation of plasma EBV-DNA during treatment in pediatric EBV-associated hemophagocytic lymphohistiocytosis
by: Wenzhi Zhang, et al.
Published: (2024-09-01)

EBV DNA methylation profiles and its application in distinguishing nasopharyngeal carcinoma and nasal NK/T-cell lymphoma
by: Cao-Li Tang, et al.
Published: (2024-01-01)

LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion
by: Yu Xiang, et al.
Published: (2023-09-01)

Latent yet lethal primary nodal EBV-positive T/NK-cell lymphoma, a case report
by: Xu Han, et al.
Published: (2025-01-01)

Advancements and challenges in gastric cancer: epidemiology, biomarkers, and therapeutic strategies
by: Marina Nishimuni, et al.
Published: (2024-09-01)

EBV AND HIV-RELATED LYMPHOMA
by: Michele Bibas, et al.
Published: (2009-12-01)

EBV AND HIV-RELATED LYMPHOMA
by: Andrea Antinori, et al.
Published: (2009-11-01)

Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma
by: Joo Young Ha, et al.
Published: (2020-11-01)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
by: Daixi Ren, et al.
Published: (2020-01-01)

Machine learning analysis reveals tumor stiffness and hypoperfusion as biomarkers predictive of cancer treatment efficacy
by: Demetris Englezos, et al.
Published: (2024-06-01)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
by: Youhai Jiang, et al.
Published: (2020-03-01)

IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS
by: Alana Kennedy-Nasser, et al.
Published: (2009-11-01)

IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS
by: Helen Heslop, et al.
Published: (2009-11-01)

EBV‐positive B‐cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency
by: Akira Satou, et al.
Published: (2021-10-01)

GNA14 may be a potential prognostic biomarker in nasopharyngeal carcinoma
by: Jinrong Hao, et al.
Published: (2024-11-01)

Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?
by: Xudong Zhang, et al.
Published: (2018-10-01)

DeepTI: A deep learning-based framework decoding tumor-immune interactions for precision immunotherapy in oncology
by: Jianfei Ma, et al.
Published: (2022-03-01)

Patient Nutrition: An Overlooked Yet Emerging Variable in the Precision Oncology Equation
by: Ashley E. Holly, et al.
Published: (2020-08-01)

Gp350-targeted CAR-T therapy in EBV-positive Burkitt lymphoma: pre-clinical development of gp350 CAR-T
by: Jiajia Wang, et al.
Published: (2025-02-01)

Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic
by: Alessandra Cesano, et al.
Published: (2018-02-01)

Human Herpesvirus and the Immune Checkpoint PD-1/PD-L1 Pathway: Disorders and Strategies for Survival
by: Takayuki Murata
Published: (2021-04-01)

PD-L1 is upregulated in CD163+ tonsillar macrophages from children undergoing EBV primary infection
by: Agustina Moyano, et al.
Published: (2022-11-01)

Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer—An Opportunity for Targeted Therapy
by: Laura M. Harbin, et al.
Published: (2022-03-01)